[1] [1] Junker S, Frommer KW, Krumbholz G, et al. Expression of adipokines in osteoarthritis osteophytes and their effect on osteoblasts[J]. Matrix Biol, 2017, 62: 75-91.

[2] [2] Hu Y, Ylh-Okouma M, Ea HK, et al. Galectin-3: a key player in arthritis[J]. Joint Bone Spine, 2017, 84(1): 15-20.

[3] [3] Johannes L, Jacob R, Leffler H. Galectins at a glance[J]. J Cell Sci, 2018, 131(9): jcs208884.

[4] [4] Zhou Z, Feng Z, Sun X, et al. The role of galectin-3 in retinal degeneration and other ocular diseases: a potential novel biomarker and therapeutic target[J]. Int J Mol Sci, 2023, 24(21): 15516.

[5] [5] Caridi B, Doncheva D, Sivaprasad S, et al. Galectins in the pathogenesis of common retinal disease[J]. Front Pharmacol, 2021, 12: 687495.

[6] [6] Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis[J]. Bone, 2012, 51(2): 249-257.

[7] [7] Arad U, Madar-Balakirski N, Angel-Korman A, et al. Galectin-3 is a sensor-regulator of toll-like receptor pathways in synovial fibroblasts[J]. Cytokine, 2015, 73(1): 30-35.

[8] [8] Udomsinprasert W, Ungsudechachai T, Wunthong S, et al. Effect of galectin-3 on synovial inflammation in knee osteoarthritis via stimulating phosphatidylinositol-3-kinase/Akt pathway[J]. Int Immunopharmacol, 2023, 122: 110673.

[9] [9] Weinmann D, Schlangen K, Andr S, et al. Galectin-3 induces a pro-degradative/inflammatory gene signature in human chondrocytes, teaming up with galectin-1 in osteoarthritis pathogenesis[J]. Sci Rep, 2016, 6: 39112.

[10] [10] Chou WC, Tsai KL, Hsieh PL, et al. Galectin-3 facilitates inflammation and apoptosis in chondrocytes through upregulation of the TLR-4-mediated oxidative stress pathway in TC28a2 human chondrocyte cells[J]. Environ Toxicol, 2022, 37(3): 478-488.

[11] [11] Hu Y, Chen X, Wang S, et al. Subchondral bone microenvironment in osteoarthritis and pain[J]. Bone Res, 2021, 9(1): 20.

[12] [12] Tanaka M, Inoue H, Takahashi N, et al. AMPK negatively regulates RANKL-induced osteoclast differentiation by controlling oxidative stress[J]. Free Radic Biol Med, 2023, 205: 107-115.

[13] [13] Yang Y, Liu Z, Wu J, et al. Nrf2 mitigates RANKL and M-CSF induced osteoclast differentiation via ROS-dependent mechanisms[J]. Antioxidants (Basel), 2023, 12(12): 2094.

[14] [14] Simon D, Derer A, Andes FT, et al. Galectin-3 as a novel regulator of osteoblast-osteoclast interaction and bone homeostasis[J]. Bone, 2017, 105: 35-41.

[15] [15] Li YJ, Kukita A, Teramachi J, et al. A possible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats[J]. Lab Invest, 2009, 89(1): 26-37.

[16] [16] Xu Y, Hu J, Lv Q, et al. Endometrium-derived mesenchymal stem cells suppress progression of endometrial cancer via the DKK1-Wnt/-catenin signaling pathway[J]. Stem Cell Res Ther, 2023, 14(1): 159.

[17] [17] Zhang L, Huang Y, Lou H, et al. LGALS3BP/Gal-3 promotes osteogenic differentiation of human periodontal ligament stem cells[J]. Arch Oral Biol, 2021, 128: 105149.

[18] [18] Iacobini C, Blasetti Fantauzzi C, Bedini R, et al. Galectin-3 is essential for proper bone cell differentiation and activity, bone remodeling and biomechanical competence in mice[J]. Metabolism, 2018, 83: 149-158.

[19] [19] Janelle-Montcalm A, Boileau C, Poirier F, et al. Extracellular localization of galectin-3 has a deleterious role in joint tissues[J]. Arthritis Res Ther, 2007, 9(1): R20.

[20] [20] Newlaczyl AU, Yu LG. Galectin-3: a jack-of-all-trades in cancer[J]. Cancer Lett, 2011, 313(2): 123-128.

[21] [21] Dong R, Zhang M, Hu Q, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)[J]. Int J Mol Med, 2018, 41(2): 599-614.

[22] [22] Zhang Y, Su D, Wang Y, et al. Locally delivered modified citrus pectin - a galectin-3 inhibitor shows expected anti-inflammatory and unexpected regeneration-promoting effects on repair of articular cartilage defect[J]. Biomaterials, 2022, 291: 121870.

[23] [23] Chen Y, Su D, Zheng J, et al. Intra-articular injection of modified citrus pectin and hyaluronate gel induces synergistic effects in treating osteoarthritis[J]. Int J Biol Macromol, 2024, 276(Pt 1): 133840.

[24] [24] Partain BD, Bracho-Sanchez E, Farhadi SA, et al. Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats[J]. Arthritis Res Ther, 2023, 25(1): 173.

[25] [25] Kong K, Li B, Chang Y, et al. Delivery of FGF18 using mRNA-LNP protects the cartilage against degeneration via alleviating chondrocyte senescence[J]. J Nanobiotechnology, 2025, 23(1): 34.

[26] [26] An X, Zhou Q, Sheng S, et al. Enhanced chondrogenic potential and osteoarthritis treatment using cyaonoside a-induced msc delivered via a hyaluronic acid-based hydrogel system[J]. Aging Dis, 2025, [Epub ahead of print].